## Distribution

<table>
<thead>
<tr>
<th>Copies</th>
<th>Copy No.</th>
<th>Office/Department</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Approval and Implementation

This plan is hereby accepted for implementation and supersedes all previous editions.

Signatories to the CHEMPACK Response Plan

Bruce Greenstein
Department of Health and Hospitals
Secretary

J. T. Lane
Department of Health and Hospitals
Interim Assistant Secretary

Doris G. Brown, MS, RN
Center for Community Preparedness
Director

Glennis P. Gray, MSN, BSN, RN-BC
Strategic National Stockpile
Statewide Nurse Consultant

Melissa Guillory
Region 2
Regional Administrator

Juliette Stefanski, MD
Region 4
Regional Administrator

David Holcombe, MD
Region 6
Regional Administrator

Steve McAdams
Region 8
Regional Administrator

Jimmy Guidry, MD
Department of Health and Hospitals
State Health Officer

Rosanne Prats, MHA ScD
Department of Health and Hospitals
Executive Director, Emergency Preparedness

Takeisha Davis, MD
Center for Community Health
Assistant State Health Officer

Avis Gray, RN
Region 1
Regional Administrator

AP Landry
Region 3
Regional Administrator

BJ Foch, MD
Region 5
Regional Administrator

Jerre Perry
Region 7
Regional Administrator

David Thomas
Region 9
Regional Administrator
Leah Michael
Department of Health and Hospitals
State Pharmacist

Mark Ryan
Poison Control Director

Keith Phillips
Center For Community Preparedness
Program Manager

Major David Stanton
Louisiana State Police
SNS Security Lead

CAPTAIN MARK RICHARDS
Foreword

CHEMPACK is a program of the U S Department of Health and Human Services’ Centers for Disease Control and Prevention’s (CDC) Division of Strategic National Stockpile (DSNS). It is a voluntary project which pre-positions sealed containers of federally-owned nerve agent antidotes at the local level. In Louisiana, the locations where these containers are housed are known as CHEMPACK Host Sites. These containers are to be opened in response to a nerve agent or an organophosphate (OP) incident when it is determined that the situation is beyond local emergency response capabilities.

This Louisiana CHEMPACK Response Plan defines guidance for an accidental or intentional nerve agent or organophosphate incident. The Louisiana Department of Health and Hospitals Office of Public Health, state and parish Office of Homeland Security and Emergency Preparedness, the Louisiana State Police, law enforcement, emergency medical services, fire services, hospitals and Host Sites will have to work cooperatively in establishing guidelines to ensure they effectively prepare for the use and deployment of CHEMPACK assets. The Department of Health and Hospitals Office of Public Health will work with regional stakeholders to formulate and update plans, procedures, arrangements, and agreements.

The planning process is continuous. Recipients of the Louisiana CHEMPACK Response Plan are expected to develop detailed plans, procedures, arrangements, and agreements for their organization to participate in CHEMPACK response activities, train their personnel to implement those plans, procedures, arrangements and agreements regularly, and to make modifications as needed. Changes and appendices to this plan will be issued as appropriate. Organizations finding areas of this plan that need improvement should notify the Department of Health and Hospitals Office of Public Health so that changes may be incorporated in an orderly manner.
# TABLE OF CONTENTS

Approval and Implementation......................................................................................................................... 3
Foreword ......................................................................................................................................................... 4
Confidentiality & Security Statement................................................................................................................ 6
I. Purpose and Scope......................................................................................................................................... 6
   A. Purpose ................................................................................................................................................... 6
   B. Scope ..................................................................................................................................................... 6
II. Situation and Assumptions ............................................................................................................................ 6
   A. Situation ................................................................................................................................................ 6
   B. Assumptions ........................................................................................................................................... 8
III. Concept of Operations................................................................................................................................. 9
   A. Local Concept of Operations .................................................................................................................. 9
   B. State Concept of Operations ..................................................................................................................10
IV. Organization and Responsibilities .............................................................................................................12
   A. Pre-incident .........................................................................................................................................12
   B. Post-Incident ......................................................................................................................................12
   C. Unauthorized Opening of a CHEMPACK Container ...........................................................................13
   D. Responsibilities for Regional Planning ..............................................................................................13
V. Direction and Control..................................................................................................................................14
   A. CHEMPACK Notification Levels for Host Sites ...............................................................................14
VI. Administrations and Logistics.....................................................................................................................15
   A. CHEMPACK Planning Considerations ..............................................................................................15
   B. Resource Allocation .............................................................................................................................15
   C. Communication ....................................................................................................................................15
   D. Notification .........................................................................................................................................15
   E. Transportation of Patient and Staff Considerations ..........................................................................15
VII. Training, Education and Exercises .........................................................................................................16
VIII. Plan Development and Maintenance ....................................................................................................16
Acronyms and Definitions...................................................................................................................................17
Appendix A: Nerve Agent and Organophosphate Commercial Product List ..................................................22
Appendix B: Container Distribution by Public Health Region .........................................................................25
Appendix C: Container Contents ...................................................................................................................26
Appendix D: Treatment Guidelines for Pre-Hospital ....................................................................................28
Appendix E: Treatment Guidelines for Hospitals ..........................................................................................32
Appendix F: Poisoning from Nerve Agents or Organophosphates ...............................................................33
Appendix G: CHEMPACK Allocation Guidelines .........................................................................................36
Appendix H: Pharmacology of Nerve Agent Antidotes ..................................................................................46
Appendix I: Chain of Custody Form ..............................................................................................................48
Appendix J: CHEMPACK General Information ............................................................................................49
Appendix K: Sample CHEMPACK Health Alert Network ............................................................................51
Confidentiality & Security Statement

Persons reading this document should consider it to be CONFIDENTIAL. The information contained within this document is sensitive and unauthorized release could reasonably be expected to cause damage. Louisiana will not release any information regarding the status of the CHEMPACK Program or the location of any CHEMPACK assets in the state.

This document is not a public record and is exempt from mandatory release of information by guidelines in the Freedom of Information Act (FOIA).

I. Purpose and Scope

A. Purpose
This plan defines state level policies and procedures relative to CHEMPACK.

B. Scope
This plan establishes policies, procedures and organizational structures for response to a nerve agent or other organophosphate incident requiring the use of CHEMPACK. Regional and local planners should use this document to establish additional guidelines and procedures to direct CHEMPACK response in their respective locales.

II. Situation and Assumptions

A. Situation

1. CHEMPACK is a federal asset which has been pre-positioned in Host Sites across Louisiana by the Louisiana Department of Health and Hospitals Office of Public Health (DHH OPH). These assets are to be used by pre-hospital services and hospitals under the direction of the Louisiana Poison Center (LPC). The Host Sites have agreed to provide housing inclusive of temperature and security monitoring devices utilizing advance technology for the CHEMPACK assets within their facilities for the good of the citizens of Louisiana. They do not own the CHEMPACK assets.

2. CHEMPACK is intended to be a supplement to existing state and local caches of medications and supplies that could be used to respond to a nerve agent or organophosphate incident. Nationally, CHEMPACK is known as a Tier II asset. Existing stores of medications and supplies that could be accessed prior to opening a CHEMPACK Container include those held by Metropolitan Medical Response System (MMRS) organizations and other pre-hospital and hospital caches purchased with emergency preparedness grant funds. The response to a nerve agent or organophosphate incident should be implemented in phases based upon the severity of the incident. The phases are as follows:

a) Tier I: Utilization of local or readily available resources. If it appears that the incident warrants a response greater than that afforded by resources available in Tier I, then Tier II should be initiated as early as an escalated need is identified.
b) Tier II: Request and use CHEMPACK resources by telephoning the Louisiana Poison Center (LPC) at 800-222-1222 or 318-813-3317.

3. Terrorist groups may use a nerve agent or other organophosphates in an attack. Many organophosphate substances commonly used as insecticides are readily available and produce similar toxic effects to those observed after exposure to a nerve agent.

4. The toxic effects of nerve agents and other organophosphates require immediate medical and pharmaceutical intervention. Death or long term medical care is a distinct possibility, especially in the absence of rapid intervention with appropriate antidote therapies.

5. Rapid, potentially life-saving medical care following a nerve agent or an organophosphate exposure may be necessary in both the pre-hospital and hospital settings.

6. The early recognition of symptoms consistent with nerve agent or organophosphate exposure and the rapid delivery of appropriate medical care directly affect a person’s ability to survive exposure to these substances. A list of potential nerve agents and organophosphate substances are included as Appendix A.

7. Louisiana has deployed 30 CHEMPACK Containers in approved secure locations. The number and type of CHEMPACK Containers located in each of Louisiana’s nine Office of Public Health regions can be found as Appendix B. The CHEMPACK Containers are designated by their respective contents as Emergency Medical Service (EMS) or Hospital Containers. The EMS Containers have a large number of auto-injectors with a small amount of multi-dose vials of medications and are primarily intended for field use. The quantity of medications found in an EMS Container is sufficient to treat approximately 454 patients. Hospital Containers have a large quantity of multi-dose vials of medications with a small number of auto-injectors and are primarily intended for use in the hospital setting. The quantity of medications available in a Hospital Container is sufficient to treat approximately 1000 patients.

8. The medications in CHEMPACK Containers, both EMS and Hospital Containers are the same three drugs: atropine, pralidoxime (2-PAM) and diazepam. These are the only drugs contained in a CHEMPACK Container. Appendix C includes the specific type and amounts of medication for the EMS and Hospital Containers. Treatment guidelines for pre-hospital and hospitals are included as Appendix D and E. Asset allocations based on the number of patients is included as Appendix G. Additional information regarding the action of the medications for patients exposed to a nerve agent or organophosphates can be found in Appendix H.

9. A CHEMPACK Buffer of atropine and pralidoxime sufficient to treat approximately five patients for 12 hours is co-located at each Host Site housing a CHEMPACK Hospital Container. The CHEMPACK Buffer medications are provided in multi-dose vials. The CHEMPACK Buffers are intended to prevent the opening of a CHEMPACK Container in an incident where only a few patients have been exposed and require treatment. The contents of the Buffer can be found in Appendix C.

10. The contents of the CHEMPACK Containers participate in the federal Shelf Life Extension Program (SLEP). This program allows for extension of expiration dates of the products based on testing by the federal government, as long as the contents are maintained in a controlled,
monitored environment. Once the numbered seal on a CHEMPACK Container is broken, the extended shelf life afforded by the SLEP program is lost. If an event occurs and a Container is opened the contents may indicate that they are expired but may be used due to SLEP inclusion. Once a Container has been opened, if the expiration date posted on the product inside the Container has passed, the drugs are now considered expired and may not be used for a subsequent incident. Expired medications must be discarded in accordance with the Louisiana Board of Pharmacy rules and regulations. Replacement of CHEMPACK Container contents is not assured. For this reason, utmost confidence should be used when making a decision to open a CHEMPACK Container.

11. Nerve agents and organophosphate substances are hazardous in both liquid and vapor form. While commonly referred to as nerve “gas” the substances are not by definition gasses, but are volatile and can be inhaled in vapor form. Skin exposure can also result in toxicity. The toxic effects of nerve agents and other organophosphate substances can occur within seconds with death potentially occurring within minutes of the initial exposure. Appendix F contains information regarding poisoning by nerve agents and organophosphates.

The Louisiana Poison Center is available to assist in determining that the symptoms observed may be the result of a nerve agent or organophosphate poisoning, to provide consultation and/or to provide advice on medical treatment to an incident commander, EMS provider, hospital or any other person involved in the response to an incident involving these substances. Appendix J contains general information about CHEMPACK.

The Louisiana Poison Center can be reached at 800-222-1222 or 318-813-3317

B. Assumptions

1. There are many factors that could affect the number of potential victims of a nerve agent or organophosphate release. These include the agent used, the terrain of the release location and the atmospheric conditions at the time of the release.

2. Following the release of a nerve agent or organophosphate, the number of patients could quickly overwhelm the resources available.

3. EMS/Haz Mat teams will triage at or near the scene of the incident.

4. It may not be possible to save all victims. Triage principles will be used to minimize loss of life. This is necessary to ensure that the greatest numbers of patients survive.

5. Accepted treatment guidelines should be followed. Treatment and dosing guidelines for the pre-hospital and hospital settings can be found in Appendices D and E.

6. A delay in therapy can greatly extend the amount of time a patient requires care, postponing discharge from healthcare facilities.

7. Patients exposed to organophosphate insecticides or other organophosphate substances may require treatment with much larger amounts of atropine and pralidoxime than patients exposed to nerve agents such as Sarin, Soman, Tabun, GF or VX.
III. Concept of Operations

A. Local Concept of Operations

1. Initial response to a nerve agent or organophosphate incident will occur at the local level. Request to use of CHEMPACK assets will be made by an incident commander or other healthcare provider.

2. The use of CHEMPACK should never be delayed by a prolonged request or authorization process. The CDC and Louisiana Department of Health and Hospitals (DHH) authorize the Louisiana Poison Center to direct a Host Site to break the seal of a CHEMPACK Container.

3. The LPC will consult with the requesting party to determine the likelihood that a nerve agent or organophosphate incident has occurred and that resources will be needed.

4. The LPC will determine whether Buffers or CHEMPACK assets are needed and will notify the Host Site to prepare for deployment.

5. During the first hours of an incident, the LPC will serve as a notification and allocation authority for CHEMPACK assets from Host Sites to EMS and between hospitals.

6. All Host Sites must be familiar with and be able to execute response planning including asset allocation in a timely manner. The Louisiana DHH requires that all internal policies and guidelines provide for the immediate opening of the CHEMPACK Container(s) and preparing the requested or pre-determined allocation of medication for transfer under the direction of the LPC.

7. The Host Sites will use the CHEMPACK Chain of Custody form located on the CHEMPACK Container and as Appendix I of this document. The facility will complete section A Host Site of the CHEMPACK Chain of Custody form, obtain the signature of the officer in section B Transporter and retain the last (pink) copy of the triplicate CHEMPACK Chain of Custody form for their records.

8. The Louisiana State Police (LSP) will complete or coordinate the transportation of CHEMPACK assets with other law enforcement agencies. Law enforcement will prioritize the timely transport of life saving antidotes from Host Sites to the on-scene Incident Commander and to receiving hospitals. Several personnel and vehicles may be required to complete this critical task.

9. Transfer from Host Sites to law enforcement will occur at the Emergency Department entrance of hospital Host Sites AND at the main entrance of fire and emergency medical service Host Sites. If the planned entrance is not available, an alternate location will be identified to the LPC and communicated to responding personnel. Response personnel must actively seek out others to ensure the rapid movement of these lifesaving assets.

10. Law enforcement will transport the CHEMPACK assets to the on-scene Incident Commander and/or to the Emergency Department entrance of receiving hospitals. Law enforcement personnel will communicate that these are lifesaving nerve agent antidotes. Professionals at the receiving location will complete section C, Receiving Site of the CHEMPACK Chain of Custody form and retain the original (white) copy of the form. Law enforcement will retain the second (yellow) copy of this form for their records.
11. After deployment, an incident will require on-going management through the coordinated efforts of numerous local, regional, state and/or federal agencies.

12. Each of the nine OPH regions will identify stakeholders to assist in CHEMPACK regional response planning. Regional templates and sample plans will be provided for regional use. The regional stakeholders include, but are not limited to:

- CHEMPACK Host Sites
- Emergency Medical Services
- Fire Services
- Hospitals within the region with Emergency Departments
  - Pharmacy personnel
  - Emergency Department personnel
  - Safety personnel
  - Security personnel
- Parish Offices of Homeland Security and Emergency Preparedness (OHSEP)
- Regional Governor’s Office of Homeland Security and Emergency Preparedness (GOHSEP)
- Local Law Enforcement
- Louisiana State Police (LSP)
- 911 or emergency communications system personnel
- Louisiana Poison Center (LPC)
- Office of Public Health
- Professional Associations
- Any additional groups or organizations identified through planning, drills, and exercises

B. State Concept of Operations

The Department of Health and Hospitals State Health Officer and the GOHSEP Director delegate the authority for utilization, coordination, and distribution of CHEMPACK assets. The Louisiana Poison Center will consult with the requesting party to determine that the symptoms of patients are consistent with a nerve agent or organophosphate exposure before assets are deployed.

13. Request to use CHEMPACK assets will be made by an on-scene Incident Commander or healthcare provider to the Louisiana Poison Center (LPC).

14. The LPC will consult with the requesting party to determine the likelihood that a nerve agent or organophosphate incident has occurred and that the CHEMPACK resources are needed.

15. Host Sites will be directed to break the seal of a CHEMPACK by the LPC.

16. During the first hours of a nerve agent response, the LPC will serve as a notification and allocation authority for CHEMPACK assets from Host Sites to EMS and between hospitals.
17. The Louisiana State Police will transport CHEMPACK assets from the CHEMPACK Host Sites to the on-scene Incident Commander and to receiving facilities. The Louisiana State Police HAZMAT Hotline is available 24/7 at 877-925-6595.

18. Law enforcement will pick up CHEMPACK assets at the Emergency Department entrance of hospital Host Sites and at the main entrance of fire and emergency medical service Host Sites.

19. Law enforcement will deliver assets to the on-scene Incident Commander and to health care professionals at the Emergency Department entrance of receiving facilities.

20. After a CHEMPACK response, the Incident Commander will document the date and location of the incident and conduct an inventory of any unused assets. This inventory will be provided to the OPH State Director of Pharmacy and the Louisiana CHEMPACK Coordinator for control and/or return of CHEMPACK assets.

21. CHEMPACK generated waste will not be returned to the Host Site, but should be disposed of by the agency or facility that uses the material. This disposal will be in accordance with approved methods of disposal.

22. The Louisiana CHEMPACK Coordinator will determine the cost of unused assets returned to the State and will negotiate any credit or replacement available from the CDC’s Strategic National Stockpile and/or CHEMPACK Programs.
IV. Organization and Responsibilities

A. Pre-incident

The CDC authorizes the State to move sites during sustainment at no cost to the state; however, the site must have already been surveyed, approved and ready for use. CHEMPACK Containers may also be moved for designated special events such as the Super Bowl, major political conventions, state fairs, large concerts, key summits, and emergencies. In the case of a special event the move may be state assisted or CHEMPACK facilitated. The same environmental conditions previously noted must be met for special event moves. The relocation of Container(s) is allowed on a temporary basis. Temporary relocation of Container(s) is subject to the following conditions:

1. The Louisiana CHEMPACK Coordinator must notify the CDC SNS program at least 48 hours prior to movement of Container(s). In the case of a special event a 30-day advance notification is required.

2. Notification of temporary relocation of Container(s) may be made via telephone or in writing. For the purposes of this notification, writing means paper or electronic transmission by fax or computer e-mail. The notification will be made to the CDC SNS Program State Consultant, the CDC CHEMPACK Regional Coordinator or the CHEMPACK Project Manager.

3. The State shall ensure that all environmental and security requirements are maintained throughout the transport process and while the Container(s) are at the remote location.

4. Any movement of CHEMPACK Container(s) not specifically directed by the CDC SNS Program shall be funded by Louisiana.

B. Post-Incident

1. After a CHEMPACK response, the Incident Commander will document the date and location of the incident and conduct an inventory of any unused assets. This inventory will be provided to the OPH State Director of Pharmacy and the Louisiana CHEMPACK Coordinator for control and/or return of CHEMPACK assets.

2. CHEMPACK generated waste will not be returned to the Host Site, but should be disposed of by the agency or facility that used the material. This disposal will be in accordance with approved methods of disposal.

3. The delivery, receipt, placement, and maintenance of any assets provided to return a Container to its full complement of contents will be coordinated by the Louisiana CHEMPACK Coordinator with the CDC CHEMPACK Program.

4. If a CHEMPACK Container is decommissioned, any and all equipment, Containers, and other material originally supplied when the Container was placed or modified will be returned to the
CDC CHEMPACK Program. The decommission process will be coordinated with the Louisiana CHEMPACK Coordinator.

5. There is currently no funding source available to replace CHEMPACK assets. However, requests for replenishment of supplies should be made to the CDC SNS Program by the Louisiana CHEMPACK Coordinator as soon as possible following an incident. The CDC SNS Program will attempt to secure funding to replace and restock supplies used in response to an incident.

C. Unauthorized Opening of a CHEMPACK Container

1. If a Container is inadvertently opened, the Host Site DEA registrant is to notify the Louisiana CHEMPACK Coordinator immediately upon discovering the open container. The Louisiana Office of Public Health is available 24/7 at 800-256-2748.

2. An inventory of the Container contents will be conducted by the Host Site and provided to the OPH State Director of Pharmacy, as soon as possible following an unauthorized opening. The circumstances surrounding the opening will accompany the inventory.

3. The Louisiana CHEMPACK Coordinator will notify the CDC CHEMPACK Program and seek guidance regarding the disposition of the assets in the opened Container.

D. Responsibilities for Regional Planning

Local CHEMPACK response requirements will be defined in service, hospital, Host Site, parish and regional response plans. Considerations include:

**Fire and Emergency Medical Services**
- Establish Incident Command
- Haz Mat Operation
- Allocation of resources
  - Personnel
  - Supplies
  - Antidotes
  - Transport

**Hospitals**
- Establish Incident Command
- Haz Mat Operation
- Allocation of resources
  - Personnel
  - Supplies
  - Antidotes
  - Transport

**Security**
- Incident scene
- Hospitals
• Host sites
• Transportation

Education and Training
• Protection of Host Site locations
• Nerve agent and organophosphate pharmacology
• Recognition of symptoms related to nerve agents/Organophosphate
• Treatment of exposed patients
• FD/EMS “field response”
• Hospitals “surge response”
• Host sites participate in the development of response plans

V. Direction and Control

A. CHEMPACK Notification Levels for Host Sites

Notification level shall be determined by the Louisiana Poison Center, the Governor’s Office of Homeland Security and Emergency Preparedness and the Department of Health and Hospitals Office of Public Health. The LPC will notify the Host Sites of notification level.

1. Level 1 – STANDBY
A nerve agent or organophosphate release is suspected, CHEMPACK Host Site(s) may be notified to be aware of the possibility of an incident. A sample CHEMPACK Health Alert Notification may be found in Appendix K.

No action by the Host Site is necessary at this time.

2. Level 2 – ALERT
Conditions indicate or symptoms are consistent with a nerve agent or organophosphate release. The LPC will notify the Host Site. The Host Site should initiate response plans in anticipation of opening the CHEMPACK Container(s) or dispatch of CHEMPACK Buffers.

CHEMPACK Container is not opened at this alert level.

3. Level 3 - ACTIVATION
Conditions indicate or symptoms are consistent with a nerve agent or organophosphate release AND assets greater than those locally or readily available are necessary to meet the demands of the incident.

Activate response plan. Dispatch Buffer(s) and/or open the CHEMPACK Container and prepare contents for deployment as directed by the LPC.
VI. Administrations and Logistics

A. CHEMPACK Planning Considerations

The number of patients requiring treatment may be difficult to determine accurately. Estimates of the number of persons affected at the scene may be obtained. Individual hospital or treatment facilities should also report the number of patients actually received to the LPC. This information is needed for resource allocation. The amount of medication sent to a location should be greater than the estimated need, if possible.

B. Resource Allocation

The quantities of each medication in the CHEMPACK to be deployed to a location may be based on the number of patients. Estimated amounts based on the number of patients can be found in Appendix G. Each region will determine how assets will be shared. CHEMPACK is a federal asset being housed in locations, known as Host Sites within the State.

C. Communication

Each region will inform existing communication systems that the LPC will authorize the opening of CHEMPACK Containers at Host Site(s) or the dispatch of CHEMPACK Buffers. The LPC will also direct the transportation of CHEMPACK assets with local law enforcement and/or the Louisiana State Police.

D. Notification

Each region will decide who will be part of the regional notification tree in the response plan. The LPC will contact the Host Site(s) to authorize opening a CHEMPACK Container or dispatch of CHEMPACK Buffers. The notification plan with priorities will be included in the regional plan. A notification procedure should never delay the deployment of CHEMPACK.

E. Transportation of Patient and Staff Considerations

1. Patients
   a. Regional plans will address when patients are transported from the field to hospitals.
   b. Regional plans will include field treatment of patients.

2. Staff
   a. Regional plans will determine when and where staff will be transported.
   b. Considerations include field, EMS and hospital staffing.

3. CHEMPACK assets will be transported or coordinated by the Louisiana State Police. Transportation of other assets will require local and regional planning.
4. Identification of local stocks of Mark1 Kits, atropine, pralidoxime and diazepam should be considered in local and regional planning.
VII. Training, Education and Exercises

A. The DHH OPH maintains two training Containers for training, display and exercises. The CHEMPACK Training Containers include labeled product for allocation demonstration and practice. The CHEMPACK Training Containers are available for use by organizations upon request. The organization requesting the use of the Containers is responsible for pickup and return. The requesting organization is responsible for any damage incurred to the Containers or contents.

B. Training and Education Considerations

1. Local request procedures
2. Training aids and support available
3. Responsibilities associated with assuming custody
4. Allocation of CHEMPACK assets
5. Antidote dosing and administration of treatment (field, transport, and hospital)
6. Supportive care issues (ventilation, eye/skin/oral care, etc.)
7. Monitoring for delayed effects
8. Returning unused CHEMPACK assets
9. Waste disposal
10. EMS and Hospitals use of CHEMPACK assets

VIII. Plan Development and Maintenance

A. Major changes that affect the Situation and Assumptions, Concept of Operations, Assignment of Responsibilities, and Direction and Control will be made as necessary. Major changes shall be approved by the Secretary of the Department of Health and Hospitals, the State Health Officer and the Director of the Governor’s Office of Homeland Security and Emergency Preparedness. The authority to revise and/or update routine changes, i.e., implementing procedures, resource inventories, and notification or recall lists is given to regional planning personnel.

B. All changes, revisions, and/or updates shall be forwarded to the Louisiana CHEMPACK Coordinator for review, editing, publication and distribution to all stakeholders.

C. An update or review shall be conducted on an annual basis.
**Acronyms and Definitions**

**2PAM:** Pralidoxime chloride. Used to separate the agent from acetyl cholinesterase.

**ABCs:** Airway, Breathing, Circulation.

**AChE:** Acetylcholine esterase, an enzyme essential for the transmission of signals through the central nervous system.

**Aerosol:** A solid particle or liquid droplet suspended in air. An aerosol is larger than a molecule and can be filtered from the air.

**All Hazards Response Plans:** Emergency Operations plans designed to cover all areas of emergency operations, including natural disasters, terrorist attacks, disease outbreaks, etc.

**AV:** atrial-ventricular.

**BT:** Bioterrorism: the use of biological agent in a terrorist incident.

**CDC:** Centers for Disease Control and Prevention.

**CHEMPACK BUFFERS:** A small box containing enough antidotes to treat three to five patients. The CHEMPACK Buffers are co-located with CHEMPACK Containers to prevent the opening of a CHEMPACK Container in an incident where only a few patients have been exposed and require treatment. The CHEMPACK Buffer contains atropine 0.4 mg/ml 20ml x 10 ml multi-dose vials and pralidoxime 1 Gm. powder 10 X 20 ml single-dose vials.

**Chemical Agent:** Chemical agents are solids, liquids, or gases that have chemical properties that produce lethal or serious effects in plants and animals. There are five main classes of chemical agents, all of which produce incapacitation, serious injury, or death: (1) nerve agents, (2) blister agents, (3) blood agents, (4) choking agents, and (5) irritation agents.

**Chemical Incident:** An event in which a chemical agent is used as a terrorist weapon.

**CNS:** Central Nervous System.

**Competent Authority:** In Louisiana, for CHEMPACK use, a Competent Authority is defined as either the on-scene incident commander or a physician.

**Concept of Operations Plan (CONPLAN):** the CONPLAN, developed during 1995 following Presidential Decision Directive (PDD)-39, provides overall guidance to Federal, State and local agencies concerning how the Federal Government would respond to a potential or actual terrorist threat or incident that occurs in the United States.

**Contingency Plan:** Targets a specific issue event that arises during the course of disaster operations and presents alternative actions to respond to the situation.

**CT:** Chemical Terrorism: the use of chemical agents in a terrorist incident.
DEA: Drug Enforcement Administration.

Dermal Exposure: Exposure to toxic substances by entry through the skin.

DHH: Louisiana Department of Health and Hospitals.

HHS: Federal Department of Health and Human Services.


DOD: Federal Department of Defense.

DOJ: Federal Department of Justice.

DRC: Designated Regional Coordinator.

DUMBBELS: Mnemonic for nerve agent symptoms: diaphoresis & diarrhea, urination, miosis, bradycardia, bronchospasm & bronchorrhea, emesis, lacrimation, and salivation & seizures.

ED: Hospital Emergency Department.

Emergency: Any natural or man-caused situation that results in or may result in substantial injury or harm to the population or substantial damage to or loss of property.

EMS: Emergency Medical Services. Usually pre-hospital medical treatment provided by paramedic or ambulance services.

ESF: Emergency Support Function.

Exercise: A simulated emergency condition carried out for the purpose of testing and evaluating the readiness of a community or organization to handle a particular type of emergency.

Expiration Date: The last date a drug or other product should be used.

FDA: Food and Drug Administration- Federal Agency.

FD/EMS: Fire Department/ Emergency Medical Service.

GI: Gastrointestinal.


HRSA: Health Resource and Services Administration: A federal agency under the Department of Health and Human Services, with a mission to improve health care access and delivery.
**Hotspots**: A term used to describe areas where the concentration of contaminants is greater than that in the surrounding areas.

**Incidence**: A measure of the number of new cases (in the form of a count or rate) of a disease or condition that occur in a specified population within a certain period.

**IV**: Intravenous.

**JRCAB**: The Joint Readiness Clinical Advisory Board.

**Kilo**: The prefix used to designate one-thousand.

**LD 50 (Lethal Dose 50%)**: The calculated dosage of a materiel that would be fatal to 50% of an exposed population.

**Liaison**: An agency official sent to another agency to facilitate interagency communications and coordination.

**Local EOP (Emergency Operations Plan)**: The local EOP focuses on essential measures for protecting the public, to include warning, emergency public information, evacuation, and shelter.

**Local Government**: Any county, city, village, town, district, or political subdivision of any State, and Indian Tribe or authorized tribal organization, or Alaska Native village or organization, including any rural community or unincorporated town or village or any other public entity.

**LPC**: Louisiana Poison Control.

**LSP**: Louisiana State Police.

**Mark I Kit**: Nerve agent antidote auto-injector kit.

**Memorandum of Agreement (MOA)**: A legal document whereby parties agree to specified actions and requirements.

**Metropolitan Medical Response System (MMRS)**: A federal program under the Department of Health and Human Services, with a mission to develop or enhance existing emergency preparedness systems.

**Mitigation**: Ongoing effort to lessen the impact disasters have on people and property to moderate in force or intensify, relieve, alleviation.

**Mortality**: A measure of the number of people who die (in the form of a count or rate) of a disease or condition within a specified population in a certain period.

**NBC CREST**: Nuclear, Biological, and Chemical Casualty and Resource Estimation Support Tool.

**Nerve Agents**: Highly toxic chemical(s) that block the action of acetylcholine esterase; an enzyme essential for the transmission of signals through the central nervous system. Hazardous in both liquid and vapor state, they can cause convulsions and death within minutes of exposure.
Non-liability: a federal agency or designated employee of a federal agency, including the American Red Cross (ARC) and its employees and volunteers, is not liable for any claim based upon the exercise or performance of or the failure to exercise or perform that function (Section 305 of the Stafford Act-performing a function under the authority of Public Law 93-288).


OP: Organophosphate.


POC: Point of contact.

Population at risk: Those persons who are susceptible to developing the disease being studied.

Push Packages: 12-hour Push Packages are caches of pharmaceuticals, antidotes, and medical supplies designed to address a variety of biologic or chemical agents. Push Packages are positioned in secure regional warehouses ready for immediate deployment to the airfield closest to the affected area following the federal decision to release SNS assets.

QA: Quality Assurance.

QC: Quality Control.

RBC: Red Blood Cell

Recovery: Recovery includes all types of emergency actions dedicated to the continued protection of the public or to promoting the resumption of normal activities in the affected area.

Recovery Plan: A plan developed by each state, with assistance from the responding federal agencies, to restore the affected area.

REMAC: Regional Emergency Medical Advisory Council.

Response: Those activities and programs designed to address the immediate and short-term effects of the onset of an emergency or disaster.

Shelf Life: The time until the expiration date of a drug or pharmaceutical.

SLEP: Shelf Life Extension Program.

SNS (Strategic National Stockpile): The SNS is a national repository of antibiotics, chemical antidotes, antitoxins, life-support medications, IV administration and airway maintenance supplies, and medical/surgical materiel for use in a declared biological or chemical terrorism incident.

SOP: Standard Operating Procedure.
**State:** For the purpose of the Federal Response Plan and as defined under Public Law 93-288, includes any state of the United States, the District of Columbia, Puerto Rico, the Virgin Islands, Guam, American Samoa, the Trust Territory of the Pacific Islands, the Commonwealth of the Northern Mariana Islands, the Federated States of Micronesia, or the Republic of the Marshall Islands.

**State Emergency Operations Plan (EOP):** The state EOP is the framework within local EOPs are created and through which the federal government becomes involved. The states play three roles: (1) they assist local jurisdictions whose capabilities are overwhelmed by an emergency; (2) they themselves respond first to certain emergencies; and (3) they work with the Federal government when Federal assistance is necessary.

**Strategic National Stockpile (SNS):** The SNS is a national repository of antibiotics, chemical antidotes, antitoxins, life-support medications, IV administration and airway maintenance supplies, and medical/surgical materiel for use in a declared biological or chemical terrorism incident.

**Strategic National Stockpile Program:** The SNS Program is designed to supplement and re-supply state and local public health agencies in the event of a biological or chemical terrorism incident anywhere, at any time within the U.S. or its territories.

**Terrorism:** As defined by the FBI. Terrorism includes the unlawful use of force or violence against persons or property to intimidate or coerce a government, the civilian population, or any segment thereof, in the furtherance of political or social objectives.

**Terrorist Incident:** The FBI defines a terrorist incident as a violent act, or an act dangerous to human life, in violation of the criminal laws of the United States or of any state, to intimidate or coerce a government, the civilian population, or any segment thereof in furtherance of political or social objectives.

**Toxicity:** The degree of danger posed by a substance to animal or plant life.

**Toxins:** Toxic substances of natural origin produced by an animal, plant, or microbe. They differ from chemical substances in that they are not manmade. Toxins may include botulism, ricin, and mycotoxins.

**Uncertainty:** The term used to describe that lack of precise knowledge in a given estimate based on the amount and quality of the evidence or data available.

**Volatilization:** Entry of contaminants into the atmosphere by evaporation from soil or water.

**Weapon of Mass Destruction (WMD):** A WMD is any device, material, or substance used in a manner, in a quantity or type, under circumstances evidencing intent to cause death or serious injury to persons or significant damage to property.
## Appendix A: Nerve Agent and Organophosphate Commercial Product List

<table>
<thead>
<tr>
<th>Agent</th>
<th>Abbreviation</th>
<th>Chemical Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tabun</td>
<td>GA</td>
<td>Ethyl N, N-dimethyl-phosphoramidocyanidate</td>
</tr>
<tr>
<td>Sarin</td>
<td>GB</td>
<td>Isopropyl-methylphosphonofluoridate</td>
</tr>
<tr>
<td>Soman</td>
<td>GD</td>
<td>1,2,2-Trimethylpropyl methylphosphonofluoridate</td>
</tr>
<tr>
<td>Cyclosarin</td>
<td>GF</td>
<td>Cyclohexyl-methylphosphonofluoridate</td>
</tr>
<tr>
<td>VX</td>
<td>VX</td>
<td>S-[2-(diisopropylamino)ethyl] methylphosphonothiolate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Brand Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>acephate</td>
<td>Orthene</td>
</tr>
<tr>
<td>azinhos-methyl</td>
<td>Gusathion, Guthion</td>
</tr>
<tr>
<td>bensulide</td>
<td>Betasan, Lescosan</td>
</tr>
<tr>
<td>bomyl</td>
<td>Swat</td>
</tr>
<tr>
<td>bromophos</td>
<td>Nexion</td>
</tr>
<tr>
<td>bromophos-ethyl</td>
<td>Nexagan</td>
</tr>
<tr>
<td>cadusafos</td>
<td>Apache, Ebulos, Rugby</td>
</tr>
<tr>
<td>carbophenothion</td>
<td>Trithion</td>
</tr>
<tr>
<td>chlorfenvinphos</td>
<td>Apachlor, Birlane</td>
</tr>
<tr>
<td>clormephos</td>
<td>Dotan</td>
</tr>
<tr>
<td>chlorphoxim</td>
<td>Baythion-Chlorpyrifos, Brodan, Dursban, Lorsban</td>
</tr>
<tr>
<td>chlorthiophos</td>
<td>Celathion</td>
</tr>
<tr>
<td>coumaphos</td>
<td>Asuntol, Co-Ral</td>
</tr>
<tr>
<td>crotoxyphos</td>
<td>Ciodrin, Cypona</td>
</tr>
<tr>
<td>crufomate</td>
<td>Ruelene</td>
</tr>
<tr>
<td>cyanofenphos</td>
<td>Surecide</td>
</tr>
<tr>
<td>cyanophos</td>
<td>Cyanox</td>
</tr>
<tr>
<td>cythioate</td>
<td>Cyflee, Proban</td>
</tr>
<tr>
<td>dEF</td>
<td>De-Green, E-Z-Off D</td>
</tr>
<tr>
<td>dematon</td>
<td>Systox</td>
</tr>
<tr>
<td>demeton-S-methyl</td>
<td>Duratox, Metasystoxl</td>
</tr>
<tr>
<td>dialifor</td>
<td>Torak</td>
</tr>
<tr>
<td>diazinon</td>
<td></td>
</tr>
<tr>
<td>dichlorfenthion</td>
<td>VC-13, Nemacide</td>
</tr>
<tr>
<td>dichlorvos</td>
<td>DDVP, Vapone</td>
</tr>
<tr>
<td>dicrotophos</td>
<td>Bidrin</td>
</tr>
<tr>
<td>dimefos</td>
<td>Hanane, Pestox XIV</td>
</tr>
<tr>
<td>dimethoate</td>
<td>Cygon, DeFend</td>
</tr>
<tr>
<td>dioxathion</td>
<td>Deinav</td>
</tr>
<tr>
<td>disulfoton</td>
<td>Disyston</td>
</tr>
<tr>
<td>Chemical</td>
<td>Brand Names</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>ditalimfos</td>
<td></td>
</tr>
<tr>
<td>edifenfos</td>
<td></td>
</tr>
<tr>
<td>endothion</td>
<td></td>
</tr>
<tr>
<td>EPBP</td>
<td>S-Seven</td>
</tr>
<tr>
<td>EPN</td>
<td></td>
</tr>
<tr>
<td>ethion</td>
<td>Ethanox</td>
</tr>
<tr>
<td>ethoprop</td>
<td>Mocap</td>
</tr>
<tr>
<td>ethyl parathion</td>
<td>E605, Parathion, Thiophos</td>
</tr>
<tr>
<td>etrimfos</td>
<td>Ekamet</td>
</tr>
<tr>
<td>famphur</td>
<td>Bash, Bo-Ana, Famfos</td>
</tr>
<tr>
<td>fenamiphos</td>
<td>Nemacur</td>
</tr>
<tr>
<td>fenitrothion</td>
<td>Accothion, Agrothion, Sumithion</td>
</tr>
<tr>
<td>fenophosphon</td>
<td>Agritox, Trichloronate</td>
</tr>
<tr>
<td>fensulfothion</td>
<td>Dasanit</td>
</tr>
<tr>
<td>fenothion</td>
<td>Baytex, Entex, Tiguvon</td>
</tr>
<tr>
<td>fonofos</td>
<td>Dyfonate, N-2790</td>
</tr>
<tr>
<td>formothion</td>
<td>Anthro</td>
</tr>
<tr>
<td>fosthietan</td>
<td>Nem-A-Tak</td>
</tr>
<tr>
<td>heptenophos</td>
<td>Hostaquick</td>
</tr>
<tr>
<td>hiometon</td>
<td>Ekatin</td>
</tr>
<tr>
<td>hosalone</td>
<td>Zoline</td>
</tr>
<tr>
<td>IBP</td>
<td>Kitazin</td>
</tr>
<tr>
<td>iodofenphos</td>
<td>Nuvalol-N</td>
</tr>
<tr>
<td>isazofos</td>
<td>Brace, Miral, Triumph</td>
</tr>
<tr>
<td>isofenphos</td>
<td>Amaze, Oftanol</td>
</tr>
<tr>
<td>isoxathion</td>
<td>E-48, Karpheos,</td>
</tr>
<tr>
<td>leptophos</td>
<td>Phosvel</td>
</tr>
<tr>
<td>malathion</td>
<td>Cythion</td>
</tr>
<tr>
<td>mephosfolan</td>
<td>Cytrolane</td>
</tr>
<tr>
<td>merphos</td>
<td>Easy off-D, Folex</td>
</tr>
<tr>
<td>methamidophos</td>
<td>Monitor</td>
</tr>
<tr>
<td>methidathion</td>
<td>Supracide, Ultracide</td>
</tr>
<tr>
<td>methyl parathion</td>
<td>E 601, Penncap-M</td>
</tr>
<tr>
<td>methyl trithion</td>
<td></td>
</tr>
<tr>
<td>mevinphos</td>
<td>Duraphos, Phosdrin</td>
</tr>
<tr>
<td>mipafox</td>
<td>Isopestox, Pestox XV</td>
</tr>
<tr>
<td>monocrotophos</td>
<td>Azpdom</td>
</tr>
<tr>
<td>Naled</td>
<td>Dibrom</td>
</tr>
<tr>
<td>oxydemethon-methyl</td>
<td>Metasystox-R</td>
</tr>
<tr>
<td>oxydeprofos</td>
<td>Metasystox-S</td>
</tr>
<tr>
<td>phencapton</td>
<td>G 28029</td>
</tr>
<tr>
<td>phenthioate, dimethioate</td>
<td>Phenthioate</td>
</tr>
<tr>
<td>phorate</td>
<td>Rampart, Thimet</td>
</tr>
<tr>
<td>phosalone</td>
<td>Azofene, Zolone</td>
</tr>
<tr>
<td>phosfolan</td>
<td>Cylan, Cylane</td>
</tr>
<tr>
<td>phosmet</td>
<td>Imidian, Prolate</td>
</tr>
<tr>
<td>Compound</td>
<td>Generic Name</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>phosphamidon</td>
<td>Dimecron</td>
</tr>
<tr>
<td>phostebupirim</td>
<td>Aztec</td>
</tr>
<tr>
<td>Phoxim</td>
<td>Baythion</td>
</tr>
<tr>
<td>pirimiphos-ethyl</td>
<td>Primicid</td>
</tr>
<tr>
<td>pirimphos-methyl</td>
<td>Actellic</td>
</tr>
<tr>
<td>profenofos</td>
<td>Curacron</td>
</tr>
<tr>
<td>propetamphos</td>
<td>Safrotin</td>
</tr>
<tr>
<td>propyl thiopyro-phosphate</td>
<td>Aspon</td>
</tr>
<tr>
<td>prothoate</td>
<td>Fac</td>
</tr>
<tr>
<td>pyrazophos</td>
<td>Afugan, Curamil</td>
</tr>
<tr>
<td>pyridaphenthion</td>
<td>Ofunack</td>
</tr>
<tr>
<td>quinalphos</td>
<td>Bayrusil</td>
</tr>
<tr>
<td>Runnel</td>
<td>Fenchlorphos, Korlan</td>
</tr>
<tr>
<td>schradan</td>
<td>OMPA</td>
</tr>
<tr>
<td>sulfotep</td>
<td>Bladafum, Dithione, Thiopep</td>
</tr>
<tr>
<td>suiprofos</td>
<td>Bolstar, Helothion</td>
</tr>
<tr>
<td>temephos</td>
<td>Abate, Abathion</td>
</tr>
<tr>
<td>terbufos</td>
<td>Contraven, Counter</td>
</tr>
<tr>
<td>tetrachlorvinphos</td>
<td>Gardona, Rabon</td>
</tr>
<tr>
<td>tetraethyl pyrophosphate</td>
<td>TEPP</td>
</tr>
<tr>
<td>triazophos</td>
<td>Hostathion</td>
</tr>
<tr>
<td>trichlorfon</td>
<td>Dipterex, Dylox, Neguvon, Proxol</td>
</tr>
</tbody>
</table>
Appendix B: Container Distribution by Public Health Region
Appendix C: Container Contents

EMS CONTAINER – Treats ~454 Patients

<table>
<thead>
<tr>
<th>Item</th>
<th>Quantity</th>
<th>Total Units in Container</th>
<th>Number of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark I Auto Injector</td>
<td>1200</td>
<td>240</td>
<td>5</td>
</tr>
<tr>
<td>Atropine Sulfate 0.4 mg/ml 20 ml</td>
<td>100</td>
<td>100</td>
<td>1</td>
</tr>
<tr>
<td>Pralidoxime 1Gm inj 20 ml vial</td>
<td>276</td>
<td>276</td>
<td>1</td>
</tr>
<tr>
<td>Atropen 0.5 mg</td>
<td>144</td>
<td>144</td>
<td>1</td>
</tr>
<tr>
<td>Atropen 1.0 mg</td>
<td>144</td>
<td>144</td>
<td>1</td>
</tr>
<tr>
<td>Diazepam 5mg/ml auto-injector</td>
<td>300</td>
<td>150</td>
<td>2</td>
</tr>
<tr>
<td>Diazepam 5mg/ml, 10ml vial</td>
<td>50</td>
<td>50</td>
<td>1</td>
</tr>
<tr>
<td>Sterile Water for Injection 20cc vials</td>
<td>200</td>
<td>100</td>
<td>2</td>
</tr>
<tr>
<td>Sensaphone 2050</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Satco C DEA Container</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

HOSPITAL CONTAINER – Treats ~1000 Patients

<table>
<thead>
<tr>
<th>Item</th>
<th>Quantity</th>
<th>Total Units in Container</th>
<th>Number of Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark I Auto Injector</td>
<td>480</td>
<td>240</td>
<td>2</td>
</tr>
<tr>
<td>Atropine Sulfate 0.4 mg/ml 20 ml</td>
<td>900</td>
<td>100</td>
<td>9</td>
</tr>
<tr>
<td>Pralidoxime 1Gm inj 20 ml vial</td>
<td>2760</td>
<td>276</td>
<td>10</td>
</tr>
<tr>
<td>Atropen 0.5 mg</td>
<td>144</td>
<td>144</td>
<td>1</td>
</tr>
<tr>
<td>Atropen 1.0 mg</td>
<td>144</td>
<td>144</td>
<td>1</td>
</tr>
<tr>
<td>Diazepam 5mg/ml auto-injector</td>
<td>150</td>
<td>150</td>
<td>1</td>
</tr>
<tr>
<td>Diazepam 5mg/ml, 10ml vial</td>
<td>650</td>
<td>50</td>
<td>13</td>
</tr>
<tr>
<td>Sterile Water for Injection 20cc vials</td>
<td>2300</td>
<td>100</td>
<td>23</td>
</tr>
<tr>
<td>Sensaphone 2050</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Satco C DEA Container</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
BUFFER – Treats 3 to 5 patients for~12 Hours

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Atropine Sulfate 0.4 mg/ml</strong></td>
<td>20-ml multi-dose vials</td>
</tr>
<tr>
<td><strong>Pralidoxime 1Gm inj</strong></td>
<td>20 ml multi-dose vials</td>
</tr>
<tr>
<td><strong>Sterile Water for Injection</strong></td>
<td>20 ml multi-dose vials</td>
</tr>
</tbody>
</table>
Appendix D: Treatment Guidelines for Pre-Hospital

Antidote Dosing based on Symptoms

- Diaphoresis, Diarrhea
- Urination
- Miosis
- Bradycardia, Bronchospasm, Bronchorrhea, Bronchoconstriction
- Emesis
- Lacrimation
- Salivation

Collectively, these “DUMBBELS” findings present clinically as abdominal distress and severe compromise of lung function due to excess secretions.

<table>
<thead>
<tr>
<th>Exposure</th>
<th>Symptoms</th>
<th>Initial Dosing* (EMS/Field)</th>
<th>Repeat Dosing (Transport/Hospital)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>DUMBBELS Agitation</td>
<td>Observe or MARK 1</td>
<td>Observe</td>
</tr>
<tr>
<td>Moderate</td>
<td>DUMBBELS Agitation Respiration distress</td>
<td>2 Mark 1**</td>
<td>Atropine 5-10 min 2-PAM q 30-60 min</td>
</tr>
<tr>
<td>Severe</td>
<td>DUMBBELS Respiration distress Seizures</td>
<td>3 MARK 1*** Diazepam</td>
<td>Atropine 5-10 min 2-PAM q 30-60 min Diazepam q 2-5 min</td>
</tr>
</tbody>
</table>

* Consider the use of Mark1 auto-injectors for infant/child/frail elderly ONLY in extraordinary circumstances if multi-dose not available, IV route not established and/or precise dosing is impossible.

** As quick as possible, both drugs from the auto-injector, one right after the other.

Information on Auto-Injectors

Note: Use of antidotes will not protect responders from anticipated exposures.

1. Auto-injectors are self-contained, simple, compact injection systems that come equipped with a pre-measured dose (normal adult dose) of antidote.
2. An antidote relieves, counteracts, or reverses the effects of poisons or drugs such as nerve agents.
3. The Mark 1 auto-injectors must be kept at room temperature (about 25°C 77°F) and must be protected from freezing.
4. Auto-injectors permit rapid administration of antidote, prevent needle cross-contamination between patients, and enable rapid and accurate administration to a large number of patients (even if the emergency provider and the patient are in chemical protective clothing).
5. Auto-injectors facilitate treatment by providing simple, accurate, drug administration of a pre-measured, controlled dose.

6. Auto-injectors administer a predictable drug dose that is not operator dependent.

7. MARK1 auto-injectors contain pre-measured doses of the nerve agent antidotes:
   - Atropine
   - 2-PAM Chloride (2-PAM CL; pralidoxime chloride)
   - Each auto-injector contains pre-measured amounts of Atropine (2 mg total dose per injection) and 2-PAM CL (600 mg total dose per injection).

8. **Mark1 Auto-injectors are to be used only:***
   - When specific signs and symptoms of exposure are present
   - Scene has been declared the site of a nerve agent release by a competent authority
   - Following consultation with medical control and/or Louisiana Poison Center
   - **Mark1 Auto-injectors are not to be used as a prophylaxis for personal protection.**

Mark1 Nerve Agent Antidote Auto-injector Use
Each Mark I Auto-injector contains:

- Atropine auto-injector 2mg in 0.7cc
- Pralidoxime auto-injector 600mg in 2cc

- The small injector, marked 1, is atropine – 2mg and should be given first.
- The larger injector, marked 2 is 2-PAM – 600 mg and is given after the atropine.
Preferred site of injection for infants, children and adults is the anterolateral thigh.

- Remove the safety cap from the auto-injectors.
- Apply firm, even pressure (not jabbing motion) to the injector until it pushes the needle into your thigh (or buttocks). Using a jabbing motion may result in an improper injection or injury to the thigh or buttocks.
- Firm pressure automatically triggers the coiled spring mechanism. This plunges the needle through the clothing into the muscle and at the same time injects the antidote into the muscle tissue.
- **Hold the injector firmly in place for at least 10 seconds.**
- Carefully remove the auto-injector from the injection site.
- The needle does not retract. Dispose of the auto-injector with caution.
IMPORTANT: Physicians and/or other medical personnel and emergency responders assisting evacuated victims of nerve agent exposure should avoid exposing themselves to cross-contamination by ensuring that they do not come into direct contact with the patient’s clothing.

Cautions for Use of Auto-injectors:

1) Every potential exposure in the immediate vicinity of the incident must be medically evaluated and monitored. Delayed symptoms may present anytime post incident. **Any patient ill enough to receive even one dose of atropine must be evaluated at an appropriate facility (e.g. casualty collection point, hospital, etc.).**

2) Signs or symptoms of nerve agent poisoning may reappear. Serial observations are a critical part of the management process.

3) Auto-injectors have been developed for use in the adult population. Safety and effectiveness of 2-PAM CL in children has not been established.

For additional information on the treatment of pediatric patients contact the Louisiana Poison Center at 800-222-1222 or 318-813-2217.
### Appendix E: Treatment Guidelines for Hospitals

<table>
<thead>
<tr>
<th>Patient</th>
<th>Mild/Moderate Effects¹</th>
<th>Severe Effects²</th>
<th>Other Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Child</strong></td>
<td>Atropine: 0.05mg/kg IM or IV (minimum 0.1mg, Maximum 5mg) AND 2-PAM: 25mg/kg IM or IV (maximum 2Gm IM or 1Gm IV)</td>
<td>Atropine: 0.1mg/kg IM or IV (minimum 0.1mg, maximum 5mg) AND 2-PAM: 50mg/kg IM or IV (maximum 2Gm IM or 1Gm IV)</td>
<td>Assisted ventilation for severe exposure. Repeat atropine at 2-5 minute intervals until secretions have diminished and airway resistance has decreased. Repeat 2-PAM chloride once at 30-60 minutes, then at one-hour intervals for 1-2 doses, as necessary. Diazepam for seizures: Child - 0.05 to 0.3 mg/kg IV (maximum 10 mg); Adult - 5 mg IV Other benzodiazepines (e.g. lorazepam) may provide relief. Phentolamine for 2-PAM chloride-induced hypertension: 1 mg IV for children; 5 mg IV for adults.</td>
</tr>
</tbody>
</table>

| **Adult** | Atropine: 2 to 4 mg IM or IV AND 2-PAM³: 600mg IM, or 25mg/kg IV slowly | Atropine: 6mg IM AND 2-PAM³: 1800 mg IM, or 50mg/Kg IV slowly | |

1. **Mild/Moderate effects of nerve agents** include localized sweating, muscle fasciculations, nausea, vomiting, weakness, and dyspnea.
2. **Severe effects of nerve agents** include unconsciousness, seizures, apnea, and flaccid paralysis.
3. Dose selection of 2-PAM chloride for elderly patients should be cautious (usually starting at 600 mg IM, or 25 mg/kg IV slowly) to account for the generally decreased organ functions in this population.

**NOTE:** 2-PAM chloride (2-PAM) is pralidoxime chloride, trade name Protopam®.

**CHEMPACK:** CHEMPACK is a federal program to provide nerve agent antidotes (Atropine, 2-PAM, Diazepam) during an emergency.

**Additional Assistance:** Contact the Louisiana Poison Center at 800-222-1222 or 318-813-3317 for additional information regarding dosing.
Appendix F: Poisoning from Nerve Agents or Organophosphates

Nerve agents and Organophosphate Insecticides cause the same symptoms. In fact, the Germans were researching insecticides when the extremely potent agents now referred to as the “G” (for German) agents were discovered. All of these substances work in the same manner, by inhibiting the enzyme acetyl cholinesterase.

Treatment of patients exposed to any of these substances is based upon the history of exposure, the route of exposure, and the symptoms present.

It is important to remember that symptoms following exposure may occur within seconds and progress to potentially fatal within minutes, so therapy should be initiated as quickly as possible.

Routes of Exposure

Exposure to organophosphates can occur through inhalation (breathing), dermal (skin) exposure, ocular (eye) exposure, or through the gastrointestinal tract (drinking or eating).

Patient History

- Symptoms following exposure to a nerve agent can occur within seconds. Symptom onset following dermal exposure may be delayed up to 18 hours post exposure.
- A history of possible exposure combined with classic physical signs and symptoms help make the diagnosis.
- Most nerve agents have little or no odor. Some commercially available organophosphate insecticides have a very strong odor.

Physical

Physical findings vary according to the route of exposure, the age of patient, and the specific chemical.

- Muscarinic findings may include the following:
  - Diaphoresis, Diarrhea
  - Urination
  - Miosis
  - Bradycardia, Bronchospasm, Bronchorrhea, Bronchoconstriction
  - Emesis
  - Lacrimation
  - Salivation

  Collectively, these “DUMBBELS” findings present clinically as abdominal distress and severe compromise of lung function due to excess secretions.

- Nicotinic findings may include the following:
  - Muscle fasciculations (twitching)
- Fatigue
- Paralysis
- Respiratory muscle weakness
- Diminished respiratory effort
- Tachycardia
- Hypertension

- CNS findings may include the following:
  - Anxiety
  - Restlessness
  - Confusion
  - Headache
  - Slurred speech
  - Ataxia
  - Seizures
  - Coma
  - Central respiratory paralysis
  - Altered level of consciousness and/or hypotonia

Medical Care:

- Pre-hospital care
  - Ensure airway support and ventilation and perform endotracheal intubation, if necessary, to support the patient before arrival.
  - Circulatory support with intravenous (IV) access, fluids, and cardiac and pulse oximetry monitoring can facilitate safe transport.
  - Decontamination is of the utmost importance in minimizing continued exposure and to protect providers and other patients from contamination. Decontamination involves removing the entire patient's clothing and washing him or her completely with water and soap.
  - By describing the scene, prevalent odors, or other casualties, pre-hospital providers may provide important clues to the presence of exposure.
  - If caregivers in the pre-hospital setting are able to make the diagnosis of organophosphate poisoning then treatment can begin in the pre-hospital setting with the administration of antidotal therapy.
  - Consultation with the staff of the Louisiana Poison Center at 800-222-1222 can aid in making the diagnosis.

- Emergency Department and Hospital Care
  - Patients who are inadequately decontaminated may expose rescue personnel and hospital staff to the toxin.
  - Assess the patient's airway, breathing, and circulation (ABCs). Secure the airway and perform cardiovascular resuscitation if needed. Endotracheal intubation may be necessary for airway protection and ventilator support.
If the patient's condition is stable, decontamination is the next priority. Pre-hospital providers may also need decontamination. The dermal decontamination of exposed individuals is a priority before they enter the emergency department where they can contaminate other patients and staff members.

- Gastric decontamination with activated charcoal should be performed in all cases of significant exposure because of the entero-hepatic recirculation common with these compounds.
- Severe exposures require expeditious antidotal therapy. Atropine is used to dry excess secretions and to ease respiratory tension.
- Atropine should be used in doses sufficient to dry secretions. Dose atropine to drying of respiratory secretions without regard to changes in heart rate or pupil size. Continued repeat dosing of atropine should occur as needed to control excess secretions.
- Pralidoxime (2-PAM) is used to break the bond between the agent and the acetyl cholinesterase molecule. 2-PAM aids in treating the muscular weakness associated with exposure to a nerve agent or other organophosphate.
- Seizures should be treated with diazepam (Valium) or other benzodiazepine like lorazepam (Ativan).

Consultations:

- Consult a medical toxicologist or the Louisiana Poison Center at 800-222-1222 for patient management assistance.
- Consult a critical care specialist early in severe poisonings for on-going care outside the Emergency Department.
Appendix G: CHEMPACK Allocation Guidelines

This guideline provides a method by which the assets of the two types of CHEMPACK (EMS or Hospital) Containers may be deployed. Personnel who will be a part of the team that opens the Container, gathers, sorts, packages, and deploys CHEMPACK assets should be familiar with these guidelines.

Assets and Case Sizes Defined:
1. **Mark 1 Kits** – Each case contains a total of 240 Mark 1 Kits packaged in 8 smaller boxes of 30 auto-injectors (case size: 13.25" ht x 19" wd x 13.5" long and weighs 39.5 lbs)

2. **Atropine Sulfate 0.4mg/mL** – Each case contains a total of 100 multiple doses vials packaged in four flats of 25 vials.
   (Case size: 6.13" ht x 5.63" wd x 13.5" long and weighs 10 lbs)

3. **Pralidoxime 1gram vials** – Case contains a total of 276 vials packaged in 46 boxes of six 1 gram vials.
   (Case size: 11.81" ht x 14" wd x 12.31" long and weighs 19.5 lbs.)

4. **Atropen® 0.5mg auto-injectors** – Each case contains 144 auto-injectors packaged in 12 smaller boxes of 12 auto-injectors.
   (Case size: 14" ht x 10.5" wd x 19.18" long and weighs 12 lbs.)

5. **Atropen® 1mg auto-injectors** – Each case contains 144 auto-injectors packaged in 12 smaller boxes of 12 auto-injectors.
   (Case size: 14" ht x 10.5" wd x 19.18" long and weighs 12 lbs.)

6. **Diazepam 10mg/2ml auto-injectors** – Each case contains 150 auto-injectors packaged in 10 smaller boxes of 15 auto-injectors.
   (Case size: 9.5" ht x 8.5" wd x 24.24" long and weighs 20 lbs)

7. **Diazepam 5mg/mL 10mL** – Each case contains 50 multiple dose vials packaged in smaller boxes of five 10mL vials.
   (Case size: 6" ht x 6.5" wd x 2.75" long and weighs 1 lb.)

8. **Sterile Water for Injection 20mL single use vials** – Each case contains 100 vials packaged in four flats of 25 vials.
   (Case size: 11.25" ht x 11.25" wd x 10" long and weighs 17.21 lbs)
Basic Principles:

1. **TIMELY RESPONSE IS CRITICAL!**

2. Attempts will be made to avoid opening or dividing smaller boxes or flats within the larger cases. This will allow for a minimum of additional handling and which would slow the packaging and transportation of the assets further.

3. Education of all personnel who may be involved in this process is essential to make rapid deployment possible.

EMS Container Allocations

Each EMS Container treats up to 454 patients

Halves Allocation Method (~227 patients per site)

<table>
<thead>
<tr>
<th>Asset and Amount</th>
<th>SITE ONE</th>
<th>SITE TWO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark 1 Kits, 1200 auto-injectors</td>
<td>20 boxes (600 Mark 1 Kits)</td>
<td>20 boxes (600 Mark 1 Kits)</td>
</tr>
<tr>
<td>Atropine Sulfate 0.4mg/mL 20mL, 100 vials</td>
<td>2 flats (50 vials)*</td>
<td>2 flats (50 vials)*</td>
</tr>
<tr>
<td>Pralidoxime 1 gram vials, 276 vials</td>
<td>23 boxes (138 vials) *</td>
<td>23 boxes (138 vials) *</td>
</tr>
<tr>
<td>Atropen® 0.5mg, 144 auto-injectors</td>
<td>6 boxes (72 auto-injectors) *</td>
<td>6 boxes (72 auto-injectors) *</td>
</tr>
<tr>
<td>Atropen® 1mg, 144 auto-injectors</td>
<td>6 boxes (72 auto-injectors) *</td>
<td>6 boxes (72 auto-injectors) *</td>
</tr>
<tr>
<td>Diazepam 10mg, 300 auto-injectors</td>
<td>1 case (150 auto-injectors)</td>
<td>1 case (150 auto-injectors)</td>
</tr>
<tr>
<td>Diazepam 5mg/mL 10mL vials, 50 vials</td>
<td>5 boxes (25 vials)</td>
<td>5 boxes (25 vials)</td>
</tr>
<tr>
<td>Sterile Water for Injection 20mL vial, 200 vials</td>
<td>1 case (100 vials) *</td>
<td>1 case (100 vials) *</td>
</tr>
</tbody>
</table>

* Cases of these items must be opened to retrieve individual boxes or flats.
EMS Container Allocations

Thirds Allocation Method (~151 patients per site)

<table>
<thead>
<tr>
<th>Asset and Amount</th>
<th>SITE ONE</th>
<th>SITE TWO</th>
<th>SITE THREE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mark 1 Kits, 1200 auto-injectors</strong></td>
<td>2 cases (480 Mark 1 Kits)</td>
<td>2 cases (480 Mark 1 Kits)</td>
<td>1 cases (120 Mark 1 Kits)</td>
</tr>
<tr>
<td>Atropine Sulfate 0.4mg/mL 20mL, 100 vials</td>
<td>2 flats (50 vials) **</td>
<td>1 flat (25 vials) **</td>
<td>1 flat (25 vials) **</td>
</tr>
<tr>
<td>Pralidoxime 1 gram vials, 276 vials</td>
<td>16 boxes (96 vials) **</td>
<td>15 boxes (90 vials) **</td>
<td>15 boxes (90 vials) **</td>
</tr>
<tr>
<td>Atropen® 0.5mg, 144 auto-injectors</td>
<td>4 boxes (48 auto-injectors) **</td>
<td>4 boxes (48 auto-injectors) **</td>
<td>4 boxes (48 auto-injectors) **</td>
</tr>
<tr>
<td>Atropen® 1mg, 144 auto-injectors</td>
<td>4 boxes (48 auto-injectors) **</td>
<td>4 boxes (48 auto-injectors) **</td>
<td>4 boxes (48 auto-injectors) **</td>
</tr>
<tr>
<td>Diazepam 10mg, 300 auto-injectors</td>
<td>7 boxes (105 auto-injectors) **</td>
<td>7 boxes (105 auto-injectors) **</td>
<td>6 boxes (90 auto-injectors) **</td>
</tr>
<tr>
<td>Diazepam 5mg/mL 10mL vials, 50 vials</td>
<td>4 boxes (20 vials)**</td>
<td>3 boxes (15 vials)**</td>
<td>3 boxes (15 vials)**</td>
</tr>
<tr>
<td>Sterile Water for Injection 20mL vial, 200 vials</td>
<td>3 flats (75 vials)**</td>
<td>3 flats (75 vials)**</td>
<td>2 flats (50 vials)**</td>
</tr>
</tbody>
</table>

* Cases of these items must be opened to retrieve individual boxes or flats.

* *Due to the rapid need for the Mark 1 Kits, further handling and division is not advised. It is better to transport full cases to the field instead of attempting to further divide the assets in a more even fashion.
EMS Container Allocations

Fourths Allocation Method (~113 patients per site)

<table>
<thead>
<tr>
<th>Asset and Amount</th>
<th>SITE ONE</th>
<th>SITE TWO</th>
<th>SITE THREE</th>
<th>SITE FOUR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mark 1 Kits, 1200 auto-injectors</strong></td>
<td>2 cases (480 Mark 1 Kits)</td>
<td>1 case (240 Mark 1 Kits)</td>
<td>1 case (240 Mark 1 Kits)</td>
<td>1 case (240 Mark 1 Kits)</td>
</tr>
<tr>
<td>*Atropine Sulfate 0.4mg/mL, 20mL, 100 vials</td>
<td>1 flat (25 vials)</td>
<td>1 flat (25 vials)</td>
<td>1 flat (25 vials)</td>
<td>1 flat (25 vials)</td>
</tr>
<tr>
<td>*Pralidoxime 1 gram, 276 vials</td>
<td>12 boxes (72 vials)</td>
<td>12 boxes (72 vials)</td>
<td>12 boxes (72 vials)</td>
<td>10 boxes (60 vials)</td>
</tr>
<tr>
<td>*Atropen 0.5mg, 144 auto-injectors</td>
<td>3 boxes (36 auto-injectors)</td>
<td>3 boxes (36 auto-injectors)</td>
<td>3 boxes (36 auto-injectors)</td>
<td>3 boxes (36 auto-injectors)</td>
</tr>
<tr>
<td>*Atropen 1mg, 144 auto-injectors</td>
<td>3 boxes (36 auto-injectors)</td>
<td>3 boxes (36 auto-injectors)</td>
<td>3 boxes (36 auto-injectors)</td>
<td>3 boxes (36 auto-injectors)</td>
</tr>
<tr>
<td>*Diazepam 10mg, 300 auto-injectors</td>
<td>5 boxes (75 auto-injectors)</td>
<td>5 boxes (75 auto-injectors)</td>
<td>5 boxes (75 auto-injectors)</td>
<td>5 boxes (75 auto-injectors)</td>
</tr>
<tr>
<td>*Diazepam 5mg/mL, 10mL vials, 50 vials</td>
<td>3 boxes (15 vials)</td>
<td>3 boxes (15 vials)</td>
<td>3 boxes (15 vials)</td>
<td>1 box (5 vials)</td>
</tr>
<tr>
<td>*Sterile Water for Injection 20mL, 200 vials</td>
<td>2 flats (50 vials)</td>
<td>2 flats (50 vials)</td>
<td>2 flats (50 vials)</td>
<td>2 flats (50 vials)</td>
</tr>
</tbody>
</table>

* Cases of these items must be opened to retrieve individual boxes or flats.

* *Due to the rapid need for the Mark 1 Kits, further handling and division is not advised. It is better to transport full cases to the field instead of attempting to further divide the assets in a more even fashion.
## Hospital Container Allocations

### Each Hospital Container treats up to 1000 patients

**Halves Allocation Method (500 patients per hospital)**

<table>
<thead>
<tr>
<th>Asset and Amount</th>
<th>Hospital One</th>
<th>Hospital Two</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark 1 Kits, 480 auto-injectors</td>
<td>1 case (240 Mark 1 Kits)</td>
<td>1 case (240 Mark 1 Kits)</td>
</tr>
<tr>
<td>Atropine Sulfate 0.4mg/mL 20mL, 900 vials</td>
<td>5 cases (500 vials)</td>
<td>4 cases (400 vials)</td>
</tr>
<tr>
<td>Pralidoxime 1 gram vials, 2760 vials</td>
<td>5 cases (1380 vials)</td>
<td>5 cases (1380 vials)</td>
</tr>
<tr>
<td>Atropen® 0.5mg, 144 auto-injectors</td>
<td>*6 boxes (72 auto-injectors)</td>
<td>*6 boxes (72 auto-injectors)</td>
</tr>
<tr>
<td>Atropen® 1mg, 144 auto-injectors</td>
<td>*6 boxes (72 auto-injectors)</td>
<td>*6 boxes (72 auto-injectors)</td>
</tr>
<tr>
<td>Diazepam 10mg, 150 auto-injectors</td>
<td>*5 boxes (75 auto-injectors)</td>
<td>*5 boxes (75 auto-injectors)</td>
</tr>
<tr>
<td>Diazepam 5mg/mL 10mL vials, 650 vials</td>
<td>7 cases (350 vials)</td>
<td>6 cases (300 vials)</td>
</tr>
<tr>
<td>Sterile Water for Injection 20mL vial, 2800 vials</td>
<td>14 cases (1400 vials)</td>
<td>14 cases (1400 vials)</td>
</tr>
</tbody>
</table>

* Cases of these items must be opened to retrieve individual boxes or flats.
Hospital Container Allocations

Thirds Allocation Method (333 patients per hospital)

<table>
<thead>
<tr>
<th>Asset and Amount</th>
<th>Hospital One</th>
<th>Hospital Two</th>
<th>Hospital Three</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark 1 Kits, 480 auto-injectors</td>
<td>*6 boxes (180 Mark 1 Kits)</td>
<td>*5 boxes (150 Mark 1 Kits)</td>
<td>*5 boxes (150 Mark 1 Kits)</td>
</tr>
<tr>
<td>Atropine Sulfate 0.4mg/mL 20mL, 900 vials</td>
<td>3 cases (300 vials)</td>
<td>3 cases (300 vials)</td>
<td>3 cases (300 vials)</td>
</tr>
<tr>
<td>Pralidoxime 1 gram vials, 2760 vials</td>
<td>4 cases (1104 vials)</td>
<td>3 cases (828 vials)</td>
<td>3 cases (828 vials)</td>
</tr>
<tr>
<td>Atopen® 0.5mg, 144 auto-injectors</td>
<td>*4 boxes (48 auto-injectors)</td>
<td>*4 boxes (48 auto-injectors)</td>
<td>*4 boxes (48 auto-injectors)</td>
</tr>
<tr>
<td>Atopen® 1mg, 144 auto-injectors</td>
<td>*4 boxes (48 auto-injectors)</td>
<td>*4 boxes (48 auto-injectors)</td>
<td>*4 boxes (48 auto-injectors)</td>
</tr>
<tr>
<td>Diazepam 10mg, 150 auto-injectors</td>
<td>*4 boxes (60 auto-injectors)</td>
<td>*3 boxes (45 auto-injectors)</td>
<td>*3 boxes (45 auto-injectors)</td>
</tr>
<tr>
<td>Diazepam 5mg/mL 10mL vials, 650 vials</td>
<td>5 cases (250 vials)</td>
<td>4 cases (200 vials)</td>
<td>4 cases (200 vials)</td>
</tr>
<tr>
<td>Sterile Water for Injection 20mL vial, 2800 vials</td>
<td>10 cases (1000 vials)</td>
<td>9 cases (900 vials)</td>
<td>9 cases (900 vials)</td>
</tr>
</tbody>
</table>

* Cases of these items must be opened to retrieve individual boxes or flats.
## Hospital Container Allocations

**Foursths Allocation Method (250 patients per hospital)**

<table>
<thead>
<tr>
<th>Asset and Amount</th>
<th>Hospital One</th>
<th>Hospital Two</th>
<th>Hospital Three</th>
<th>Hospital Four</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark 1 Kits, 480 auto-injectors</td>
<td>*4 boxes (120 Mark 1 Kits)</td>
<td>*4 boxes (120 Mark 1 Kits)</td>
<td>*4 boxes (120 Mark 1 Kits)</td>
<td>*4 boxes (120 Mark 1 Kits)</td>
</tr>
<tr>
<td>Atropine Sulfate 0.4mg/mL 20mL, 900 vials</td>
<td>3 cases (300 vials)</td>
<td>2 cases (200 vials)</td>
<td>2 cases (200 vials)</td>
<td>2 cases (200 vials)</td>
</tr>
<tr>
<td>Pralidoxime 1 gram vials, 2760 vials</td>
<td>3 cases (828 vials)</td>
<td>3 cases (828 vials)</td>
<td>2 cases (552 vials)</td>
<td>2 cases (552 vials)</td>
</tr>
<tr>
<td>Atropen® 0.5mg, 144 auto-injectors</td>
<td>*3 boxes (36 auto-injectors)</td>
<td>*3 boxes (36 auto-injectors)</td>
<td>*3 boxes (36 auto-injectors)</td>
<td>*3 boxes (36 auto-injectors)</td>
</tr>
<tr>
<td>Atropen® 1mg, 144 auto-injectors</td>
<td>*3 boxes (36 auto-injectors)</td>
<td>*3 boxes (36 auto-injectors)</td>
<td>*3 boxes (36 auto-injectors)</td>
<td>*3 boxes (36 auto-injectors)</td>
</tr>
<tr>
<td>Diazepam 10mg, 150 auto-injectors</td>
<td>*3 boxes (45 auto-injectors)</td>
<td>*3 boxes (45 auto-injectors)</td>
<td>*2 boxes (30 auto-injectors)</td>
<td>*2 boxes (30 auto-injectors)</td>
</tr>
<tr>
<td>Diazepam 5mg/mL 10mL vials, 650 vials</td>
<td>4 cases (200 vials)</td>
<td>3 cases (150 vials)</td>
<td>3 cases (150 vials)</td>
<td>3 cases (150 vials)</td>
</tr>
<tr>
<td>Sterile Water for Injection 20mL vial, 2800 vials</td>
<td>6 cases (600 vials)</td>
<td>6 cases (600 vials)</td>
<td>6 cases (600 vials)</td>
<td>5 cases (500 vials)</td>
</tr>
</tbody>
</table>

* Cases of these items must be opened to retrieve individual boxes or flats.
Hospital Container Allocations

For any number of patients that exceed the treatment capacity of available CHEMPACK Buffers the following allocation will be used for 100 or fewer patients. There are enough supplies in a hospital pack to supply 8 sites with 100 or fewer patients from the allocations below, or fewer sites with re-supply amounts available.

Tenths Allocation (100 patients)

<table>
<thead>
<tr>
<th>Asset and Amount</th>
<th>Each Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark 1 Kits, 480 auto-injectors</td>
<td>*2 boxes (60 Mark 1 Kits)</td>
</tr>
<tr>
<td>Atropine Sulfate 0.4mg/mL 20mL, 900 vials</td>
<td>1 case (100 vials)</td>
</tr>
<tr>
<td>Pralidoxime 1 gram vials, 2760 vials</td>
<td>1 case (276 vials)</td>
</tr>
<tr>
<td>Atropen® 0.5mg, 144 auto-injectors</td>
<td>*1 box (12 auto-injectors)</td>
</tr>
<tr>
<td>Atropen® 1mg, 144 auto-injectors</td>
<td>*1 box (12 auto-injectors)</td>
</tr>
<tr>
<td>Diazepam 10mg, 150 auto-injectors</td>
<td>*1 box (15 auto-injectors)</td>
</tr>
<tr>
<td>Diazepam 5mg/mL 10mL vials, 650 vials</td>
<td>1 case (50 vials)</td>
</tr>
<tr>
<td>Sterile Water for Injection 20mL vial, 2800 vials</td>
<td>3 cases (300 vials)</td>
</tr>
</tbody>
</table>

* Cases of these items must be opened to retrieve individual boxes or flats.
**Sample “Pick List”**

Your hospital site has been contacted and given directions to open 1 CHEMPACK Container. Instructions to prepare 1 one-tenths allocation are given. The following “pick list” should be used to prepare the shipment.

### One-tenths Allocation

#### Pick List

After the CHEMPACK Container seal is broken and the door is removed, collect the following and prepare for deployment. Check beside each number after those items have been removed, checked and set aside for shipment.

1. Remove 1 one case of Mark I Kits labeled with a blue sticker. Open that case, remove 2 of the boxes inside and place those 2 boxes aside for shipment.
2. Remove 1 case of atropine sulfate labeled with a green sticker. Do not open the case. Set aside for shipment.
3. Remove one case of pralidoxime labeled with a red sticker. Do not open the case. Set aside for shipment.
4. Remove the case of atropine 0.5mg auto-injectors labeled with a pink sticker. Open the case and remove 1 of the boxes inside. Place that 1 box aside for shipment.
5. Remove 1 case of atropine 1.0mg auto-injectors labeled with an orange sticker. Open the case and remove 1 of the boxes inside. Place that 1 box aside for shipment.
6. Remove 1 case of diazepam auto-injectors labeled with a brown label. Open the case and remove 1 of the boxes inside. Place that 1 box aside for shipment.
7. Remove 1 case of diazepam 5mg/ml labeled with a purple sticker. Do not open the case. Place those cases aside for shipment.
8. Remove 3 cases of sterile water for injection labeled with yellow stickers. Do not open the cases. Place those cases aside for shipment.
9. Package items removed from cases in a box and secure with tape.
Sample Legend for Color Coding

Contents may vary based on packaging.

**Mark I Kits**
Contents:
8 boxes of 30 Kits
240 total Kit’s total

**Atropine Sulfate**
0.4 mg/ml 20ml vials
Contents:
4 flats of 25 vials each
100 vials total

**Pralidoxime**
1 Gram vials
Contents:
46 boxes of 6 vials
276 vials total

**Atropen 0.5mg**
Contents:
12 boxes of 12 injectors
144 auto-injectors total

**Atropen 1.0mg**
Contents:
12 boxes of 12 injectors
144 auto-injectors total

**Diazepam 5mg/ml 10 ml vials**
Contents:
5 boxes of 10 vials each
50 vials total

**Diazepam 10mg**
Contents:
10 boxes of 15 injectors
150 auto-injectors total

**Sterile Water for Injection 20 ml vials**
Contents:
4 flats of 25 vials each
100 vials total
Appendix H: Pharmacology of Nerve Agent Antidotes

Atropine: Competitive antagonist of acetylcholine at muscarinic sites. It is used to treat gastrointestinal, pulmonary, and upper airway symptoms after known or suspected exposure to a nerve agent or organophosphate. Administer until cholinergic signs reverse. Large doses may be needed.

**Adult Dose**

0.05 mg/kg IV initially; then 1-2 mg IV q20-30min until cholinergic signs reverse

**Pediatric Dose**

<12 years: 0.02-0.05 mg/kg IV q20-30min until cholinergic signs reverse; >12 years: Administer as in adults

**Contraindications**

Documented hypersensitivity; thyrotoxicosis; narrow-angle glaucoma; tachycardia

**Interactions**

Coadministration with other anticholinergics have additive effects; may increase pharmacologic effects of atenolol and digoxin; may decrease antipsychotic effects of phenothiazine; tricyclic antidepressants with anticholinergic activity may increase effects

**Pregnancy**

C (Safety for use during pregnancy has not been established)

**Precautions**

Caution in coronary heart disease, tachycardia, congestive heart failure, cardiac arrhythmias, and hypertension; caution in peritonitis, ulcerative colitis, hepatic disease, and hiatal hernia with reflux esophagitis; in prostatic hypertrophy, prostatism can cause dysuria and catheterization may be required; may impair regulation of body temperature (caution in hot and humid weather)

2-PAM (Protopam): An agent that reactivates AChE by binding to organophosphate molecule, displacing the AChE and allowing it to once again inactivate acetylcholine. It is used to treat muscle weakness and respiratory muscle weakness in known exposure. 2-PAM must be administered before a phenomenon known as aging occurs. Aging may occur as soon as two minutes after exposure to Soman or as late as 48 hours after exposure to VX. Aging times vary by specific organophosphate substance, so 2-PAM should be administered as soon as possible after exposure. In a symptomatic patient, both 2-PAM and atropine should be administered.

**Adult Dose**

1-2 g IV over 15 min, then 500 mg/h IV until muscle strength returns
**Pediatric Dose**  
<12 years: 25-50 mg/kg IV initially, then 10-20 mg/kg/h IV until muscle strength returns;  
>12 years: 0.5-1 g IV initially, then 500 mg/h IV until muscle strength returns

**Contraindications**  
Documented hypersensitivity

**Interactions**  
AChE inhibitors may potentiate the action of barbiturates; may antagonize the effects of neostigmine, pyridostigmine, and edrophonium. Morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazines can worsen condition of patients poisoned by organophosphate insecticides or nerve agents (do not administer)

**Pregnancy**  
C (Safety for use during pregnancy has not been established)

**Precautions**  
Rapid injection can cause tachycardia, laryngospasm, muscle rigidity, pain at injection site, blurred vision, diplopia, impaired accommodation, dizziness, drowsiness, nausea, tachycardia, hypertension, and hyperventilation; can precipitate myasthenia crisis in patients with myasthenia gravis and muscle rigidity in healthy volunteers; renal dysfunction increases serum levels because excreted in urine; can transiently increase creatinine phosphokinase level; aspartate aminotransferase and/or alanine aminotransferase levels increase in 1 of 6 patients.

**Further Inpatient Care**

- Admit patients to the hospital if they require therapy with atropine or 2-PAM. Monitoring, respiratory support, and assisted ventilation may be needed.
- Consult the poison center for information regarding the specific agent and patient management guidance.

**Further Outpatient Care**

- Patients with minor or no symptoms of toxicity after inhalational exposure to a nerve agent or other organophosphate exposure may be discharged from the Emergency Department after 6 hours of observation.
- Patients with dermal exposure should be monitored for an extended period. Symptoms following dermal exposure, even if decontamination has been performed, may be delayed for up to 18 hours post exposure.
- Discharged patients usually do not require outpatient medications, but should be counseled about the duration that any symptoms present may persist.

**Transfer**

- Transfer pediatric patients with severe life-threatening exposures to a facility with a pediatric intensivist and intensive care unit.

Patients should be clinically stable before transfer.
Appendix I: Chain of Custody Form
CHEMPACK CHAIN OF CUSTODY FORM

Site (Circle) 1 2 3 4
CONTAINER NUMBER (4 Digits): __________ DATE: ______________

A. HOST SITE

STEP 1: COMPLETE THE HOST SITE AND RECEIVING SITE INFORMATION BELOW.

<table>
<thead>
<tr>
<th>Name, Address, and Phone Number of HOST Facility</th>
<th>Name, Address, and Phone Number of RECEIVING Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact Person: _____________________________</td>
<td>Contact Person: _______________________________</td>
</tr>
<tr>
<td>Title: _________________________________</td>
<td>Title: _________________________________</td>
</tr>
<tr>
<td>Name of HOST Facility: _________________</td>
<td>Name of RECEIVING Site: _______________________</td>
</tr>
<tr>
<td>Address: _____________________________</td>
<td>Address: ________________________________</td>
</tr>
<tr>
<td>Phone Number: _____________________________</td>
<td>Phone Number: _____________________________</td>
</tr>
</tbody>
</table>

STEP 2: REMOVE THE REQUESTED MATERIAL FROM THE CHEMPACK CONTAINER USING THE PICK/PACKING LIST.
STEP 3: AFTER ALL MATERIAL IS READY FOR TRANSPORT PLACE THIS FORM ALONG WITH THE PICK/PACKING LIST WITH THE MATERIAL FOR THIS SITE.
STEP 4: DELIVER MATERIAL TO THE DESIGNATED PICK UP LOCATION.
STEP 5: ENTER THE NAME AND A CONTACT PHONE NUMBER FOR THE PERSON TRANSPORTING THE MATERIAL:

Name: ______________________________________________ Contact Phone Number: _____________________________

STEP 5: ENTER THE TIME THE MATERIAL IS RELEASED FOR TRANSPORT:
______________________________________

STEP 6: IMPORTANT- REMOVE AND RETAIN THE BOTTOM COPY OF THIS FORM FOR YOUR RECORDS. GIVE THE OTHER COPIES TO THE PERSON TRANSPORTING THE MATERIAL.

B. TRANSPORTER

STEP 1: ENTER THE NAME, TITLE AND PHONE # OF THE PERSON MATERIALS ARE RELEASED TO AT THE RECEIVING SITE:

Name ____________________________________ Title ___________________________ Phone: _________________________

STEP 2: REMOVE AND RETAIN THE BOTTOM COPY OF THIS FORM FOR YOUR RECORDS AFTER DELIVERY OF THE MATERIAL IS COMPLETE.

C. RECEIVING SITE

STEP 1: PERFORM INVENTORY OF MATERIAL RECEIVED. COMPARE TO PICK/PACKING LIST.
STEP 2: VERIFY MATERIAL IS ACCOUNTED FOR YES ______ NO ______

Name and title of person performing inventory Name _____________________________ Title _____________________________

STEP 3: DISTRIBUTE MATERIAL FOR USE.
STEP 4: IF DESCREPANCIES IN INVENTORY DELIVERED ARE NOTED CONTACT THE HOST SITE AT THE NUMBER LISTED ABOVE.
STEP 5: RETAIN THE COPY OF THIS FORM DELIVERED WITH THE MATERIAL FOR YOUR RECORDS.
Appendix J: CHEMPACK General Information

CHEMPACK
ANTIDOTES FOR:
Nerve Agent or Organophosphate EXPOSURES

Clinically presents as abdominal distress and severe compromise of lung function due to excess secretions

**D**iaphoresis, Diarrhea
**U**rination
**M**iosis
**B**radycardia, Bronchospasm, Bronchorrhea, Bronchoconstriction
**E**metics
**L**acrimation
**S**alivation

Medications are atropine, pralidoxime and diazepam as auto-injectors and multi-dose vials

Call Louisiana Poison Center at 1-800-222-1222 to consult and request CHEMPACK assets
CHEMPACK FACT SHEET

What is CHEMPACK?
CHEMPACK is nerve agent antidotes placed in secure containers by the federal government. Thirty of these containers have been pre-positioned across Louisiana. Nerve agent antidotes are an important component of all hazard preparedness. Terrorists have access to many different types of chemical agents and nerve agents are considered a likely choice. A deliberate or accidental nerve agent release could occur anywhere and at any time in the United States. A release could require a large supply of nerve agent antidotes. The pre-positioning of CHEMPACK containers will expedite delivery of these nerve agent antidotes to a disaster site to save lives. CHEMPACK is a component of the Center for Disease Control and Prevention’s Strategic National Stockpile.

What medicines are in CHEMPACK?
The medications in CHEMPACK are antidotes for nerve agents or organophosphate poisoning. The three medications in CHEMPACK are atropine, pralidoxime and diazepam in Mark 1 Kits and multi-does vials. Mark 1 Kits are often used in the field. Multi-dose vials allow titrated treatment in hospitals. These medications could be used by emergency medical services (EMS), law enforcement and hospitals in Louisiana. CHEMPACK was designed to supplement and re-supply local and state responders in the event of a chemical emergency event.

Where are the CHEMPACK assets?
The CHEMPACK assets have been pre-positioned across Louisiana. The location of the CHEMPACK containers is kept confidential. This confidentiality protects these valuable medications and sites that host them.

How will CHEMPACK be used?
It is expected that a nerve agent incident will be identified locally. CHEMPACK will be used by first responders in the field and by health care professionals in hospitals. The Louisiana Poison Control Center will provide consultation on symptoms of nerve agent or organophosphate poisoning with first responders and health care professionals. The Louisiana Poison Control Center can be contacted 24/7 by telephoning 800-222-1222.

Allocation of assets will be coordinated by the Louisiana Poison Center in the first hours of an incident. Pre-event planning has begun with local and state response partners. These include the Governor’s Office of Homeland Security and Emergency Preparedness, parish Office of Homeland Security and Emergency Preparedness, Louisiana State Police, Louisiana Sheriff’s Association, local law enforcement, the Department of Health and Hospital Office of Public Health, Bureau of Emergency Medical Service, EMS providers, Louisiana Hospital Association, hospitals and the Louisiana Poison Center. CHEMPACK will be an addition to existing state, regional, local and facility plans.

Has CHEMPACK ever been used?
The CHEMPACK assets have never been used to respond to a chemical terrorism event in the United States. These medications were used in 1995 following a sarin nerve agent attack on the Tokyo mass transit system. Pre-positioning and planning for the use of these nerve agent antidotes are an important part of chemical terrorism preparedness for the United States and Louisiana.

Other Resources
The Centers for Disease Control and Prevention has detailed information about the Strategic National Stockpile on its Web site at: http://www.bt.cdc.gov/stockpile/
Appendix K: Sample CHEMPACK Health Alert Network

At [insert time] on [insert date] first responders reported persons with signs and symptoms consistent with nerve agent or organophosphate poisoning at [insert location information]. Local assets are to be used first. Medications from the federal cache CHEMPACK include Mark 1 Kits, atropine, pralidoxime and diazepam and are available if local assets are insufficient. The Louisiana Poison Center will direct allocation and transportation of CHEMPACK assets based on the current situation. They may be contacted at 800-222-1222. Attached are general treatment guidelines for pre-hospital and hospital settings. These guidelines do not supersede facility specific protocols. Additional information will be provided as it becomes available.

Treatment Guidelines for Pre-Hospital

Antidote Dosing based on Symptoms

- Diaphoresis, Diarrhea
- Urination
- Miosis
- Bradycardia, Bronchospasm, Bronchorrhea, Bronchoconstriction
- Emesis
- Lacrimation
- Salivation

Collectively, these “DUMBBELS” findings present clinically as abdominal distress and severe compromise of lung function due to excess secretions.

<table>
<thead>
<tr>
<th>Exposure</th>
<th>Symptoms</th>
<th>Initial Dosing* (EMS/Field)</th>
<th>Repeat Dosing (Transport/Hospital)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>DUMBBELS Agitation</td>
<td>Observe or MARK 1</td>
<td>Observe</td>
</tr>
<tr>
<td>Moderate</td>
<td>DUMBBELS Agitation</td>
<td>2 Mark 1**</td>
<td>Atropine 5-10 min 2-PAM q 30-60 min</td>
</tr>
<tr>
<td>Severe</td>
<td>DUMBBELS Respiratory distress Seizures</td>
<td>3 MARK 1*** Diazepam</td>
<td>Atropine 5-10 min 2-PAM q 30-60 min Diazepam q 2-5 min</td>
</tr>
</tbody>
</table>

* Consider the use of Mark1 Kits for infant/child/frail elderly ONLY in extraordinary circumstances if multi-dose not available, IV route not established and/or precise dosing is impossible.

** As quick as possible, both drugs from the auto-injector, one right after the other.

Treatment Guidelines for Hospitals
### CHEMPACK Plan

<table>
<thead>
<tr>
<th>Patient</th>
<th>Mild/Moderate Effects$^1$</th>
<th>Severe Effects$^2$</th>
<th>Other Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child</td>
<td><strong>Atropine:</strong> 0.05mg/kg IM or IV (minimum 0.1mg, maximum 5mg) <strong>AND</strong> 2-PAM: 25mg/kg IM or IV (maximum 2Gm IM or 1Gm IV)</td>
<td><strong>Atropine:</strong> 0.1mg/kg IM or IV (minimum 0.1mg, maximum 5mg) <strong>AND</strong> 2-PAM: 50mg/kg IM or IV (maximum 2Gm IM or 1Gm IV)</td>
<td>Assisted ventilation for severe exposure. Repeat atropine at 2-5 minute intervals until secretions have diminished and airway resistance has decreased. Repeat 2-PAM chloride once at 30-60 minutes, then at one-hour intervals for 1-2 doses, as necessary. Diazepam for seizures: Child - 0.05 to 0.3 mg/kg IV (maximum 10 mg); Adult - 5 mg IV Other benzodiazepines (e.g. lorazepam) may provide relief. Phentolamine for 2-PAM chloride-induced hypertension: 1 mg IV for children; 5 mg IV for adults.</td>
</tr>
<tr>
<td>Adult</td>
<td><strong>Atropine:</strong> 2 to 4 mg IM or IV <strong>AND</strong> 2-PAM$^3$: 600mg IM, or 25mg/kg IV slowly</td>
<td><strong>Atropine:</strong> 6mg IM <strong>AND</strong> 2-PAM$^3$: 1800 mg IM, or 50mg/Kg IV slowly</td>
<td></td>
</tr>
</tbody>
</table>

4. **Mild/Moderate effects of nerve agents** include localized sweating, muscle fasciculation’s, nausea, vomiting, weakness and dyspnea.
5. **Severe effects of nerve agents** include unconsciousness, seizures, apnea, and flaccid paralysis.
6. Dose selection of 2-PAM chloride for elderly patients should be cautious (usually starting at 600 mg IM, or 25 mg/kg IV slowly) to account for the generally decreased organ functions in this population.

**NOTE:** 2-PAM chloride (2-PAM) is pralidoxime chloride, trade name Protopam®.

**CHEMPACK:** CHEMPACK is a federal program to provide nerve agent antidotes (Atropine, 2-PAM, Diazepam) during an emergency.

**Additional Assistance:** Contact the Louisiana Poison Center at 1-800-222-1222 or 318 813-3317 for additional information regarding dosing.